Clinical, etiological and antimicrobial susceptibility profile of pediatric urinary tract infections in a tertiary care hospital of Nepal.
Antimicrobial resistance
MDR
MRSA
UTI
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
29 01 2019
29 01 2019
Historique:
received:
22
10
2018
accepted:
18
01
2019
entrez:
31
1
2019
pubmed:
31
1
2019
medline:
23
2
2020
Statut:
epublish
Résumé
Urinary tract infection (UTI) is one of most common pediatric infections. The study was designed to assess the clinical profile, common bacterial microorganisms causing UTI and their antimicrobial susceptibility patterns at B. P. Koirala Institute of Health Sciences (BPKIHS) hospital. This is a prospective cross-sectional study conducted at Department of Microbiology and Infectious Diseases for 6 months (January to June 2018). A total of 1962 non-repetitive urine specimens (midstream, nappy pad, catheter aspirated) of pediatric patients (0-14 years age) suspected of UTI were obtained in the Microbiology laboratory. Clinical data was obtained from requisition form and hospital software. Culture and bacterial identification was done by using standard microbiological guidelines. Antimicrobial susceptibility testing was done by Kirby-Bauer disc diffusion method following clinical and laboratory standards institute (CLSI) guidelines. Resistance to methicillin and vancomycin were confirmed by calculating minimum inhibitory concentration using broth dilution method. Among 1962 samples, 314 (16%) were positive for bacterial infection. Fever, irritability and poor feeding was the most common symptoms in neonates while older children presented with fever and urinary symptoms. E. coli was reported the most common etiological agent (53%), followed by Enterococcus faecalis (22%), Klebsiella pneumoniae (7%) and Staphylococcus aureus (7%). Multidrug resistant (MDR) isolates accounted for 32% of isolates, while 5% were extensively drug resistant (XDR). Fourty percentage of gram-negative bacilli were ESBL producer, 38% of S. aureus were methicillin resistant Staphylococcus aureus (MRSA) and 5% E. faecalis were vacomycin resistant enterococci (VRE). E coli was highly resistant to Ampicillin (87%), Ceftriaxone (62%) and Ofloxacin (62%). Amikacin (11% resistance) and Nitrofurantoin (5% resistance) are the most effective drugs for gram-negative bacilli (GNB) while vancomycin and linezolid are functional against gram-positive cocci. High-level antimicrobial resistance was observed in pediatric UTI with alarming incidence superbugs like MDR, XDR, ESBL and MRSA. Regular surveillance should be carried out to determine the local prevalence of organisms and antimicrobial susceptibilities in order to guide the proper management of children.
Sections du résumé
BACKGROUND
Urinary tract infection (UTI) is one of most common pediatric infections. The study was designed to assess the clinical profile, common bacterial microorganisms causing UTI and their antimicrobial susceptibility patterns at B. P. Koirala Institute of Health Sciences (BPKIHS) hospital.
METHODS
This is a prospective cross-sectional study conducted at Department of Microbiology and Infectious Diseases for 6 months (January to June 2018). A total of 1962 non-repetitive urine specimens (midstream, nappy pad, catheter aspirated) of pediatric patients (0-14 years age) suspected of UTI were obtained in the Microbiology laboratory. Clinical data was obtained from requisition form and hospital software. Culture and bacterial identification was done by using standard microbiological guidelines. Antimicrobial susceptibility testing was done by Kirby-Bauer disc diffusion method following clinical and laboratory standards institute (CLSI) guidelines. Resistance to methicillin and vancomycin were confirmed by calculating minimum inhibitory concentration using broth dilution method.
RESULTS
Among 1962 samples, 314 (16%) were positive for bacterial infection. Fever, irritability and poor feeding was the most common symptoms in neonates while older children presented with fever and urinary symptoms. E. coli was reported the most common etiological agent (53%), followed by Enterococcus faecalis (22%), Klebsiella pneumoniae (7%) and Staphylococcus aureus (7%). Multidrug resistant (MDR) isolates accounted for 32% of isolates, while 5% were extensively drug resistant (XDR). Fourty percentage of gram-negative bacilli were ESBL producer, 38% of S. aureus were methicillin resistant Staphylococcus aureus (MRSA) and 5% E. faecalis were vacomycin resistant enterococci (VRE). E coli was highly resistant to Ampicillin (87%), Ceftriaxone (62%) and Ofloxacin (62%). Amikacin (11% resistance) and Nitrofurantoin (5% resistance) are the most effective drugs for gram-negative bacilli (GNB) while vancomycin and linezolid are functional against gram-positive cocci.
CONCLUSIONS
High-level antimicrobial resistance was observed in pediatric UTI with alarming incidence superbugs like MDR, XDR, ESBL and MRSA. Regular surveillance should be carried out to determine the local prevalence of organisms and antimicrobial susceptibilities in order to guide the proper management of children.
Identifiants
pubmed: 30696410
doi: 10.1186/s12887-019-1410-1
pii: 10.1186/s12887-019-1410-1
pmc: PMC6350346
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Références
Clin Ther. 2008 Nov;30(11):2090-5
pubmed: 19108796
PLoS One. 2018 Jan 25;13(1):e0190910
pubmed: 29370234
Medicine (Baltimore). 2017 Apr;96(14):e4635
pubmed: 28383394
Indian J Med Res. 2008 Jan;127(1):85-8
pubmed: 18316858
Bol Med Hosp Infant Mex. 2017 Jul - Aug;74(4):265-271
pubmed: 29382515
Nepal Med Coll J. 2008 Jun;10(2):86-90
pubmed: 18828428
Aust Fam Physician. 2016 Aug;45(8):558-63
pubmed: 27610444
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:198-202
pubmed: 18154548
Acta Paediatr. 2012 May;101(5):451-7
pubmed: 22122295
J Microbiol Immunol Infect. 2016 Apr;49(2):243-8
pubmed: 26299351
Indian J Med Res. 2014 Jun;139(6):945-8
pubmed: 25109731
Kathmandu Univ Med J (KUMJ). 2013 Oct-Dec;11(44):319-24
pubmed: 24899328
Int J Pediatr. 2014;2014:126142
pubmed: 24959183
Microbiol Spectr. 2016 Apr;4(2):
pubmed: 27227294
J Nepal Health Res Counc. 2014 Sep-Oct;12(28):151-5
pubmed: 26032050
J Antimicrob Chemother. 2014 Dec;69(12):3259-62
pubmed: 25063776
Pol J Microbiol. 2018;67(4):517-524
pubmed: 30550238
Indian J Pharmacol. 2018 Mar-Apr;50(2):69-74
pubmed: 30100654
J Med Microbiol. 2017 Jul;66(7):927-936
pubmed: 28703700
BMC Infect Dis. 2012 Jul 19;12:158
pubmed: 22812651
Biomed Res Int. 2017;2017:4909452
pubmed: 28497052
Int J Pediatr. 2012;2012:943653
pubmed: 22888360
Klin Padiatr. 2004 Mar-Apr;216(2):83-6
pubmed: 15106080
Clin Infect Dis. 2010 Mar 1;50(5):625-63
pubmed: 20175247
Pediatrics. 2005 Sep;116(3):644-8
pubmed: 16140703
Ann Clin Microbiol Antimicrob. 2018 Jun 25;17(1):27
pubmed: 29940982
Antimicrob Resist Infect Control. 2017 Jan 11;6:9
pubmed: 28096977
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
J Clin Diagn Res. 2014 Oct;8(10):DC01-3
pubmed: 25478339
Ann Clin Microbiol Antimicrob. 2007 Mar 23;6:4
pubmed: 17378940
Pediatr Infect Dis J. 2008 Apr;27(4):302-8
pubmed: 18316994
PLoS One. 2016 Oct 24;11(10):e0165242
pubmed: 27776162
Springerplus. 2014 May 01;3:216
pubmed: 24839589
BMC Res Notes. 2012 Jan 19;5:38
pubmed: 22260454
Indian J Urol. 2016 Jan-Mar;32(1):50-6
pubmed: 26941495
Clin Microbiol Rev. 2005 Apr;18(2):417-22
pubmed: 15831830
BMJ. 2000 May 13;320(7245):1312-3
pubmed: 10807624
N Engl J Med. 2011 Jul 21;365(3):239-50
pubmed: 21774712
BMJ. 2016 Mar 15;352:i939
pubmed: 26980184
Paediatr Int Child Health. 2017 Nov;37(4):273-279
pubmed: 28978286